Futuristic global cell and gene therapy regulations based on a review of today's leading frameworks

The advancement of cell and gene therapies (CGT) represents a pivotal shift in the treatment model for cancers and a broad spectrum of other diseases, particularly rare and orphan disorders. Despite major advances, information regarding global regulatory pathways is scarce and often perplexing. Essential technicalities to approval, such as current good manufacturing practice, good laboratory practices, critical process parameters and pathways that accelerate the approval process (like orphan drug designation), are often inadvertently marginalized or overcomplicated. Furthermore, the globalization of these therapies is crucially hampered by fragmented, economically unsustainable and unreliable regulatory pathways. These regulatory challenges and the high cost of the traditional clinical trial model create significant bottlenecks for developers. We analyze the current frameworks in major jurisdictions, highlighting the technicalities in each and propose a new, harmonized global blueprint for development and approval. Key components of this proposed framework include a shift toward advanced preclinical models, adaptive trial design and patient-centric endpoints. Along with simplifying the processes for CGT developers (whether industry or academia), adopting this framework could increase the efficiency of CGT approvals, and lower the development costs. Such changes would help in achieving the goal of bench to bedside to globalization, directly translating into a more robust research atmosphere that benefits all by increasing the efficiency of CGT trial and product approvals in both developed and developing countries.